Eikon Therapeutics Inc.
EIKN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EIKN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EIKN
Eikon Therapeutics Inc. is a clinical-stage biotechnology company focused on oncology, leveraging its proprietary single molecule tracking (SMT) platform to develop novel therapies for high unmet need cancers.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Market Cap
$594.7M
Cash Runway
23.9 moLead Asset
eik1001 (Phase 2)Next Catalyst
Phase3_Topline · Dec 1, 2040Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 10 clinical trials · 2 catalysts for Eikon Therapeutics Inc..
Eikon Therapeutics Inc. is a clinical-stage biotechnology company focused on oncology, leveraging its proprietary single molecule tracking (SMT) platform to develop novel therapies for high unmet need cancers.
- Eikon is advancing a pipeline of drug candidates including EIK1001, EIK1003, EIK1004, and EIK1005 in clinical trials, and EIK1006 in preclinical development [sec_mda · as of 2026-08-13].
- The company is conducting a Phase 2/3 registrational trial for EIK1001 in combination with pembrolizumab for advanced melanoma, and a Phase 2 trial in non-small cell lung cancer [sec_mda · as of 2026-03-30].
- As of June 30, 2026, Eikon reported cash and equivalents of $142.6M, a net loss of -$88.4M, and shareholders' equity of -$571.9M [sec].
- Eikon expects its existing cash to fund operations into the second half of 2027, but anticipates needing additional capital thereafter [sec_mda · as of 2026-08-13].
- The company does not own manufacturing facilities and relies on contract manufacturing organizations (CMOs) for clinical supply [sec_mda · as of 2026-05-11].
What works
- Eikon's strategy centers on deploying its proprietary single molecule tracking (SMT) system to develop internally-derived novel therapies, which may provide a competitive advantage in drug discovery [sec_mda · as of 2026-08-13].
- The company has multiple clinical-stage candidates (EIK1001, EIK1003, EIK1004, EIK1005) targeting large oncology indications with high unmet need, potentially diversifying its pipeline [sec_mda · as of 2026-08-13].
- Eikon is conducting a Phase 2/3 registrational trial for EIK1001 in advanced melanoma, indicating a path toward potential regulatory submission [sec_mda · as of 2026-03-30].
What to weigh
- Eikon has no approved products and has incurred significant losses, with a net loss of -$88.4M for the six months ended June 30, 2026, and negative shareholders' equity of -$571.9M [sec].
- The company expects expenses to increase substantially as it advances its pipeline, and it may never achieve or sustain profitability, requiring additional capital [sec_mda · as of 2026-08-13].
- Eikon's cash runway is estimated only into the second half of 2027, and it may need to raise additional funds through equity or debt, which could be dilutive or restrictive [sec_mda · as of 2026-08-13].
- The company relies on third-party CMOs for manufacturing and has no marketing or sales organization, posing execution risks for potential commercialization [sec_mda · as of 2026-05-11].
From the filings
Quoted directly from source documents.
Eikon's strategy uses its proprietary SMT platform to develop novel therapies.
“Our strategy centers around deploying our technology platform, including our proprietary single molecule tracking, or SMT, system, to develop internally-derived novel therapies”
SEC MD&A · August 13, 2026
Eikon expects to continue incurring significant losses and needs additional capital.
“Because of the numerous risks and uncertainties associated with product development, we may never achieve or sustain profitability, and unless we are able to do so, we will need to continue to raise additional capital.”
SEC MD&A · August 13, 2026
Eikon's cash runway extends into the second half of 2027.
“Based on our current operating plan, we estimate that our existing cash, cash equivalents, and marketable securities as of the date of this Quarterly Report will be sufficient to fund our operating expenses and capital expenditures into the second half of 2027.”
SEC MD&A · August 13, 2026
Eikon is conducting a Phase 2/3 registrational trial for EIK1001 in advanced melanoma.
“We are currently conducting a Phase 2/3 registrational trial for EIK1001 in combination with pembrolizumab for the treatment of patients with advanced melanoma.”
SEC MD&A · March 30, 2026
Catalyst timeline
- 2040-12-01 · Phase3_Topline — Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to E — This is a placeholder date; actual topline results for EIK1001 or other candidates may occur earlier and should be monitored.
- 2040-12-31 · Phase3_Topline · eik1001 — Phase 3 Topline: A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in C — This is a placeholder date; actual topline results for EIK1001 may occur earlier and should be monitored.
Risks & what to watch (4)›
Key risks
- No approved products — Eikon has no products approved for sale and depends entirely on successful development and regulatory approval of its pipeline [sec_mda · as of 2026-03-30].
- Cash runway limited — Existing cash is sufficient only into H2 2027; additional capital needed thereafter, with risk of delay or termination of programs [sec_mda · as of 2026-08-13].
- Reliance on third parties — Eikon relies on CMOs for manufacturing and has no internal sales or marketing capabilities, creating execution risk [sec_mda · as of 2026-05-11].
- Negative equity position — Shareholders' equity was -$571.9M as of June 30, 2026, indicating accumulated deficits exceeding assets [sec].
What to watch
- Clinical data readouts for EIK1001 in advanced melanoma and NSCLC, including potential topline results from the Phase 2/3 registrational trial [sec_mda · as of 2026-03-30].
- Progress of EIK1003, EIK1004, and EIK1005 through Phase 1/2 trials, and advancement of EIK1006 from preclinical to clinical development [sec_mda · as of 2026-08-13].
- Future financing activities, as the company may need to raise capital before H2 2027 to continue operations [sec_mda · as of 2026-08-13].
- Any updates on collaboration or licensing agreements that could provide non-dilutive funding or strategic support [sec_mda · as of 2026-03-30].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Eikon Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Eikon Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
23.9 months
D/E 0.67 · 0% dilution
Lead: Phase 2/Phase 3
6 candidates
2 upcoming, next in ~5207d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$174.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 3,836,830 | $40.6M |
| blackrock, inc. | 3,319,379 | $35.1M |
| vanguard capital management llc | 1,938,862 | $20.5M |
| alliancebernstein l.p. | 1,022,188 | $10.8M |
| ecor1 capital, llc | 732,606 | $7.8M |
| baker bros. advisors lp | 555,555 | $5.9M |
| soros capital management llc | 484,672 | $5.1M |
| stepstone group lp | 395,340 | $4.2M |
| canada pension plan investment board | 379,024 | $4.0M |
| franklin resources inc | 350,000 | $3.7M |
Showing top 10 of 47 institutional holders of Eikon Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 8.1%
- Days to cover
- 8.0
- Shares short
- 3,313,762
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EIKN short interestFrequently asked questions
What is the AI investment thesis for Eikon Therapeutics Inc.?
Eikon Therapeutics Inc. is a clinical-stage biotechnology company focused on oncology, leveraging its proprietary single molecule tracking (SMT) platform to develop novel therapies for high unmet need cancers.
What is Eikon Therapeutics Inc.'s lead drug candidate?
Eikon Therapeutics Inc.'s most advanced tracked candidate is eik1001 (Phase 2) for NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous).
What is Eikon Therapeutics Inc.'s next catalyst?
Eikon Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to E" — expected December 1, 2040.
Who is the CEO of Eikon Therapeutics Inc.?
Dr. Roger M. Perlmutter M.D., Ph.D. is the chief executive officer of Eikon Therapeutics Inc. (EIKN).
Where is Eikon Therapeutics Inc. headquartered?
Eikon Therapeutics Inc. (EIKN) is headquartered in Millbrae, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.